PIF for Inhaled Aerosol Therapy
Research type
Research Study
Full title
Patient-specific Peak Inspiratory flow for Inhaled Aerosol Therapy
IRAS ID
344260
Contact name
Omar Usmani
Contact email
Sponsor organisation
Imperial College London,
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
It is becoming increasingly clear that efficacy of inhalation therapy in asthma and COPD patients critically depends on the patient’s breathing characteristics. In the case of therapy by a dry powder inhaler (DPI), the peak inspiratory flow that a patient can generate is critical to actual pulmonary delivery of the aerosolized drug. Depending on the type of DPI, the patient will need to overcome the DPI-specific internal resistance, by forcefully inhaling through the DPI device. While an optimal combination of patient and device is a clinical decision to make, it can be informed by the patient’s peak inspiratory flow capabilities. We have previously established in asthma and COPD patients, a mathematical relationship between a patient’s spirometric peak inspiratory flow and the peak inspiratory flow over a resistance. In this way it was possible to predict whether a patient with a given spirometric result would be able to generate sufficient inspiratory flow for the efficacious use of their DPI device.
REC name
West of Scotland REC 5
REC reference
24/WS/0152
Date of REC Opinion
12 Nov 2024
REC opinion
Further Information Favourable Opinion